G1 Therapeutics, Inc. (GTHX) Forms $26.24 Double Top; Synacor Has 1.06 Sentiment

G1 Therapeutics, Inc. (GTHX) formed double top with $28.34 target or 8.00% above today’s $26.24 share price. G1 Therapeutics, Inc. (GTHX) has $743.78M valuation. The stock decreased 0.46% or $0.12 during the last trading session, reaching $26.24. About 60,768 shares traded. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.

Synacor, Inc. operates as a technology development, multiplatform services, and revenue partner for video, Internet, and communications providers; and device manufacturers, governments, and enterprises. The company has market cap of $76.41 million. It enables its clients to provide their clients engaging, multiscreen experiences with products that require scale, and actionable data and implementation. It currently has negative earnings. The company, through its managed portals and advertising solutions, enables its clients to earn revenue by monetizing media among their consumers.

Analysts await G1 Therapeutics, Inc. (NASDAQ:GTHX) to report earnings on February, 14. After $-0.55 actual EPS reported by G1 Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.45% negative EPS growth.

The stock increased 1.28% or $0.025 during the last trading session, reaching $1.975. About 261,431 shares traded or 85.56% up from the average. Synacor, Inc. (SYNC) has risen 15.89% since January 29, 2017 and is uptrending. It has underperformed by 0.81% the S&P500.

Northpointe Capital Llc holds 0.48% of its portfolio in Synacor, Inc. for 1.65 million shares. New Jersey Better Educational Savings Trust owns 70,000 shares or 0.16% of their US portfolio. Moreover, Thompson Davis & Co. Inc. has 0.1% invested in the company for 20,700 shares. The Illinois-based Ariel Investments Llc has invested 0.09% in the stock. Ancora Advisors Llc, a Us-based fund reported 368,578 shares.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: